Added to YB: 2025-12-30
Pitch date: 2025-12-29
HROW [bullish]
Harrow, Inc.
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
Market Cap
$1.9B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
42.52
P/E
-365.47
EV/Sales
8.12
Sector
Pharmaceuticals
Category
growth
Show full summary:
The portfolio I am taking into 2026 - Harrow, Inc.
HROW: Ophthalmology co leveraging unique distribution to scale neglected eye drugs from Big Pharma at low prices. Growth drivers: Vevye (dry eye) market share gains, biosimilars scaling, MELT-300 sedative (2028+ beyond ophthalmology). Target $250M Q4/27 rev at 30-40% op margin. 2027: 20x PE, 10x EV/EBITDA for 30%+ growth thru 2029.
Read full article (1 min)